Home > Back to Publisher > Report Information

The 2009-2014 World Outlook for In-Vitro Diagnostic Hematology Products

Icon Group International, Inc.
September 27, 2008
186 Pages - SKU: ICON1955643

Abstract Table of Contents Related Reports

Countries covered: Global

This econometric study covers the world outlook for in-vitro diagnostic hematology products across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created.

This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the 230 countries of the world). This study gives, however, my estimates for the worldwide latent demand, or the P.I.E., for in-vitro diagnostic hematology products. It also shows how the P.I.E. is divided across the world’s regional and national markets. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business.

Additional Information

This econometric study covers the world outlook for in-vitro diagnostic hematology

1 INTRODUCTION: 1.1 Overview; 1.2 What is Latent Demand and the P.I.E.?; 1.3 The Methodology
2 SUMMARY OF FINDINGS: 2.1 The Worldwide Market Potential
3 AFRICA, EUROPE & THE MIDDLE EAST: 3.1 Executive Summary; 3.2 Afghanistan; 3.3 Albania; 3.4 Algeria; 3.5 Andorra; 3.6 Angola; 3.7 Armenia; 3.8 Austria; 3.9 Azerbaijan; 3.10 Bahrain; 3.11 Belarus; 3.12 Belgium; 3.13 Benin; 3.14 Bosnia and Herzegovina; 3.15 Botswana; 3.16 Bulgaria; 3.17 Burkina Faso; 3.18 Burundi; 3.19 Cameroon; 3.20 Cape Verde; 3.21 Central African Republic; 3.22 Chad; 3.23 Comoros; 3.24 Congo (formerly Zaire); 3.25 Cote d'Ivoire; 3.26 Croatia; 3.27 Cyprus; 3.28 Czech Republic; 3.29 Denmark; 3.30 Djibouti; 3.31 Egypt; 3.32 Equatorial Guinea; 3.33 Estonia; 3.34 Ethiopia; 3.35 Finland; 3.36 France; 3.37 Gabon; 3.38 Georgia; 3.39 Germany; 3.40 Ghana; 3.41 Greece; 3.42 Guinea; 3.43 Guinea-Bissau; 3.44 Hungary; 3.45 Iceland; 3.46 Iran; 3.47 Iraq; 3.48 Ireland; 3.49 Israel; 3.50 Italy; 3.51 Jordan; 3.52 Kazakhstan; 3.53 Kenya; 3.54 Kuwait; 3.55 Kyrgyzstan; 3.56 Latvia; 3.57 Lebanon; 3.58 Lesotho; 3.59 Liberia; 3.60 Libya; 3.61 Liechtenstein; 3.62 Lithuania; 3.63 Luxembourg; 3.64 Madagascar; 3.65 Malawi; 3.66 Mali; 3.67 Malta; 3.68 Mauritania; 3.69 Mauritius; 3.70 Moldova; 3.71 Monaco; 3.72 Morocco; 3.73 Mozambique; 3.74 Namibia; 3.75 Niger; 3.76 Nigeria; 3.77 Norway; 3.78 Oman; 3.79 Pakistan; 3.80 Palestine; 3.81 Poland; 3.82 Portugal; 3.83 Qatar; 3.84 Republic of Congo; 3.85 Reunion; 3.86 Romania; 3.87 Russia; 3.88 Rwanda; 3.89 San Marino; 3.90 Sao Tome E Principe; 3.91 Saudi Arabia; 3.92 Senegal; 3.93 Sierra Leone; 3.94 Slovakia; 3.95 Slovenia; 3.96 Somalia; 3.97 South Africa; 3.98 Spain; 3.99 Sudan; 3.100 Swaziland; 3.101 Sweden; 3.102 Switzerland; 3.103 Syrian Arab Republic; 3.104 Tajikistan; 3.105 Tanzania; 3.106 The Gambia; 3.107 The Netherlands; 3.108 The United Arab Emirates; 3.109 The United Kingdom; 3.110 Togo; 3.111 Tunisia; 3.112 Turkey; 3.113 Turkmenistan; 3.114 Uganda; 3.115 Ukraine; 3.116 Uzbekistan; 3.117 Western Sahara; 3.118 Yemen; 3.119 Zambia; 3.120 Zimbabwe
4 ASIA: 4.1 Executive Summary; 4.2 Bangladesh; 4.3 Bhutan; 4.4 Brunei; 4.5 Burma; 4.6 Cambodia; 4.7 China; 4.8 Hong Kong; 4.9 India; 4.10 Indonesia; 4.11 Japan; 4.12 Laos; 4.13 Macau; 4.14 Malaysia; 4.15 Maldives; 4.16 Mongolia; 4.17 Nepal; 4.18 North Korea; 4.19 Papua New Guinea; 4.20 Philippines; 4.21 Seychelles; 4.22 Singapore; 4.23 South Korea; 4.24 Sri Lanka; 4.25 Taiwan; 4.26 Thailand; 4.27 Vietnam
5 LATIN AMERICA: 5.1 Executive Summary; 5.2 Argentina; 5.3 Belize; 5.4 Bolivia; 5.5 Brazil; 5.6 Chile; 5.7 Colombia; 5.8 Costa Rica; 5.9 Ecuador; 5.10 El Salvador; 5.11 French Guiana; 5.12 Guatemala; 5.13 Guyana; 5.14 Honduras; 5.15 Mexico; 5.16 Nicaragua; 5.17 Panama; 5.18 Paraguay; 5.19 Peru; 5.20 Suriname; 5.21 The Falkland Islands; 5.22 Uruguay; 5.23 Venezuela
6 NORTH AMERICA & THE CARIBBEAN: 6.1 Executive Summary; 6.2 Antigua and Barbuda; 6.3 Aruba; 6.4 Barbados; 6.5 Bermuda; 6.6 Canada; 6.7 Cuba; 6.8 Dominica; 6.9 Dominican Republic; 6.10 Greenland; 6.11 Grenada; 6.12 Guadeloupe; 6.13 Haiti; 6.14 Jamaica; 6.15 Martinique; 6.16 Puerto Rico; 6.17 St. Kitts and Nevis; 6.18 St. Lucia; 6.19 St. Vincent and the Grenadines; 6.20 The Bahamas; 6.21 The British Virgin Islands; 6.22 The Cayman Islands; 6.23 The Netherlands Antilles; 6.24 The U.S. Virgin Islands; 6.25 The United States; 6.26 Trinidad and Tobago
7 OCEANA: 7.1 Executive Summary; 7.2 American Samoa; 7.3 Australia; 7.4 Christmas Island; 7.5 Cook Islands; 7.6 Fiji; 7.7 French Polynesia; 7.8 Guam; 7.9 Kiribati; 7.10 Marshall Islands; 7.11 Micronesia Federation; 7.12 Nauru; 7.13 New Caledonia; 7.14 New Zealand; 7.15 Niue; 7.16 Norfolk Island; 7.17 Palau; 7.18 Solomon Islands; 7.19 The Northern Mariana Island; 7.20 Tokelau; 7.21 Tonga; 7.22 Tuvalu; 7.23 Vanuatu; 7.24 Wallis and Futuna; 7.25 Western Samoa
8 DISCLAIMERS, WARRANTEES, AND USER AGREEMENT PROVISIONS: 8.1 Disclaimers & Safe Harbor; 8.2 ICON Group International, Inc. User Agreement Provisions

More Global Hematology & Oncology Reports

In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers & Microbiology Culture) – Global Trends & Forecasts to 2016 by MarketsandMarkets
The global in-vitro diagnostics (IVD) market was valued at $44 billion in 2011 and is expected to have a modest growth during the study period. ...

2012 Global Occult Blood Diagnostics Market Outlook: Test Volume and Sales Forecasts by Country by Venture Planning Group
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific ...

2012 World Cancer Diagnostic Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, ...

2012 Global Cancer Diagnostics Market Outlook: Growth Opportunities and Strategies by Venture Planning Group
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific ...

The 2012 Global Cancer Diagnostic Market Overview - Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, ...

See all reports like this >>

The 2009-2014 World Outlook for In-Vitro Diagnostic Hematology Products

Share this report

Other tasks

Research Assistance

Related Markets

Hematology & Oncology Reports

Free Alert Me service